Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Inclusion Criteria: * Signed, written, informed consent * Male or female subjects, 18 to 55 years of age. * Subject must have chronic infection HCV, genotype 1. * Serum HCV-RNA concentrations 100,000 IU/mL to 10,000,000 IU/mL * No prior treatment for HCV. * Must be negative for hepatitis B (HBV) and human immunodeficiency virus (HIV). * Must be willing to use dual method of contraception (i.e., barrier and spermicide; birth control pills and barrier) during the study. * No known hypersensitivity to study medication or to drugs chemically related to the study. Exclusion Criteria: * Prior treatment with IFN-based therapies and/or anti-viral therapies. * Women with ongoing pregnancy or breast feeding and male partners of women who are pregnant. * Reduced kidney function. * Presence of concomitant liver diseases * Signs or symptoms of hepatocellular carcinoma. * Thyroid disease currently poorly controlled on prescribed medications. * History of hemoglobinopathy. * Evidence of severe retinopathy. * Other serious medical conditions, including human immunodeficiency virus, cancer (excluding non-melanoma skin cancer), or evidence of drug or alcohol abuse. * Subjects with documented or presumed coronary artery disease, pulmonary disease, or cerebrovascular disease * Clinically significant acute or chronic illnesses. * History of severe psychiatric disease, especially depression, characterized by a suicide attempt, hospitalization for psychiatric disease, or a period of disability as a result of psychiatric disease.